Medindia

X

Zargis Receives Additional Contracts from U.S. Army

Friday, October 10, 2008 General News J E 4
Advertisement
PRINCETON, N.J., Oct. 9 Zargis Medical Corp., a spin-offfrom Siemens Corporate Research, a division of Siemens AG (NYSE: SI), and amajority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announcedthat it was awarded six additional contracts from the U.S. Army totaling$270,000. Included in these awards is $170,000 of orders for nine upgradedversions of the telemedicine pilot-systems which Zargis delivered to the Armyearlier this year. Based on the Army's successful evaluation of the initialprototypes in a large military hospital, they have decided to expand the scopeof the project and purchase these additional units.

The upgraded systems provide improved data collection quality and aredesigned to record, synchronize and analyze heart sounds, lung sounds, ECGsignals and, in some cases, blood oxygen saturation levels from patients beingcared for by remote military treatment facilities located throughout thePacific Rim. The systems will be fully integrated with an existing Armytelehealth platform.

"We're very pleased by the success of the prototype telemedicine systemsdelivered to the Army earlier this year," stated Zargis CEO John Kallassy."The demand for medical systems designed to remotely project the expertise ofcardiologists and other medical specialists is growing very rapidly -- withinboth military and civilian environments worldwide -- and it is for this reasonthat Zargis has identified the field of telemedicine as a key focus area forcommercialization of our products."

About Zargis Medical Corp.

Zargis Medical Corp. develops advanced diagnostic decision supportproducts and services for primary care physicians, pediatricians,cardiologists and other healthcare professionals. Zargis was formed in 2001when Siemens Corporate Research, a division of Siemens AG (NYSE: SI), andSpeedus Corp. co-invested to develop and market an advanced acoustictechnology designed to detect heart abnormalities identified through analysisof heart sounds.

For additional information about Zargis or Speedus Corp., contact PeterHodge at 888.773.3669 (ext. 23) or phodge@zargis.com, or visit the followingWeb sites: www.zargis.com and www.speedus.com.

Statements contained herein that are not historical facts, including butnot limited to statements about the Company's product, corporate identity andfocus, may be forward-looking statements that are subject to a variety ofrisks and uncertainties. There are a number of important factors that couldcause actual results to differ materially from those expressed in anyforward-looking statements made by the Company, including, but not limited to,the continuing development of the Company's sales, marketing and supportefforts.

SOURCE Zargis Medical Corp.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Video: American Eye-Q(R) Survey Indicates Strong N...
S
SCOLR Pharma Announces Completion of Patient Enrol...